After an acute coronary syndrome event, alirocumab may offer greater risk reductions for future cardiovascular events in patients with diabetes vs those without diabetes, according to study results published in The Lancet Diabetes & Endocrinology. In the ODYSSEY OUTCOMES trial (Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab; ClinicalTrials.gov Identifier:…
Evidence supports changing clinical practice guidelines to recommend formal weight loss programs for people with NAFLD.
In a cohort of premenopausal women with PCOS, metformin treatment for 3 months was associated with reduced bone turnover.
Critically ill patients who maintained blood glucose levels between 70 to 140 mg/dL at least 80% of the time had increased survival compared with those who did not.
Greater organ-absorbed doses of radioactive iodine seem to be positively associated with risk for death from solid cancer in patients with hyperthyroidism.
A major osteoporotic fracture was recorded in 37.5% of participants, with incidence rates of 43%, 29.2%, and 33.1% in the RA, SLE, and primary Sjögren syndrome groups, respectively.
Elderly women with osteoporosis may still be good candidates for drug treatment to prevent incident hip fracture despite competing mortality risk.
Bone turnover markers and Trabecular Bone Score might be useful tools to identify transmenopausal women who are at greater risk for bone loss.
A majority of older adults with prediabetes remain stable or revert to normoglycemia over the long term.
Mifepristone may be an effective alternative to adrenalectomy in patients with hypercortisolism caused by primary bilateral macronodular adrenal hyperplasia.
